{
    "2019-08-30": [
        [
            {
                "time": "",
                "original_text": "智飞生物董事长蒋仁生获全国非公经济人士优秀建设者称号",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "董事长",
                        "蒋仁生",
                        "非公经济",
                        "优秀建设者"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "渝股点金｜估值再次回归合理区间 涪陵榨菜值得关注",
                "features": {
                    "keywords": [
                        "渝股",
                        "涪陵榨菜",
                        "估值",
                        "合理区间"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "食品"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "康华生物：主打产品获批涉及行贿 销售费用逐年增高 其他违规处罚",
                "features": {
                    "keywords": [
                        "康华生物",
                        "主打产品",
                        "行贿",
                        "销售费用",
                        "违规处罚"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【国元医药】代理产品高速增长，后续在研可期 ——智飞生物2019H1中报点评",
                "features": {
                    "keywords": [
                        "国元医药",
                        "智飞生物",
                        "代理产品",
                        "高速增长",
                        "在研可期",
                        "2019H1中报"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物:业绩符合预期,HPV疫苗持续放量带动公司高增长",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "业绩",
                        "HPV疫苗",
                        "持续放量",
                        "高增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物2019H1中报点评:代理产品高速增长,后续在研可期",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "2019H1中报",
                        "代理产品",
                        "高速增长",
                        "在研可期"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}